Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant
Dai Chihara(The University of Texas MD Anderson Cancer Center), Robert J. Kreitman(National Cancer Institute), Constance M. Yuan(National Cancer Institute), Mark Raffeld(National Cancer Institute), Liqiang Xi(Center for Cancer Research), Seth M. Steinberg(National Institutes of Health), Katherine R. Calvo(National Institutes of Health Clinical Center), Lacey James-Echenique(MRC Laboratory of Molecular Biology), Julie Feurtado(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Evgeny Arons(National Institutes of Health), Chin‐Hsien Tai(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Irina Marić(Center for Cancer Research), Keyur P. Patel(The University of Texas MD Anderson Cancer Center)
Cited by 28
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2
|New England Journal of Medicine|2014|889
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744